Vahid Asnafi

Country flagFrance

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (16)

Thymomas are rare thymic epithelial tumors harboring a high but variable proportion of lymphocytes without obvious function. Autoimmunity is present in one third of patients at diagnosis. In this study, we performed a phenotypic, single-cell RNA sequencing and spatial analysis of both the T cells and tumoral cells. T cells at all stages of T-cell development—from immature to mature—were present in the tumor, suggesting active thymopoiesis in thymoma. However, data generated through multiple approaches suggested a maturation blockade at the double-negative to double-positive stage of T-cell development. In the mature T-cell compartment, the frequency of regulatory T cells was strongly decreased. The single-cell RNA sequencing analysis showed that the transcriptome of tumoral thymic epithelial cells (TEC) was most similar to that of nontumoral medullary TEC, but the expression of key molecules involved in positive and negative selection was defective. Multiplexed IHC consecutive staining revealed a loss of the cortex–medulla zoning in thymoma, which may be related to a decrease in the expression of T cell–targeted chemokines by tumoral TEC. Altogether, these results suggest that the thymopoiesis present in thymoma is abnormal and may be the cause of the prevalent autoimmunity observed in this disease.

Year:

2026

The Group for Research in Adult Acute Lymphoblastic Leukemia (GRAALL)-2014 trial evaluated an intensive, age-adapted protocol for adults aged 18 to 59 years with Philadelphia chromosome negative acute lymphoblastic leukemia. The trial was motivated by findings from the previous GRAALL-2005 study, which reported excessive toxicity from pediatric-inspired therapy in older patients and no added benefit from allogeneic hematopoietic stem cell transplantation (allo-HSCT) among those with an early favorable response to treatment. Thus, the GRAALL-2014 protocol aimed to reduce treatment-related toxicity in patients aged ≥45 years and to limit allo-HSCT to patients with poor measurable residual disease (MRD) responses. A total of 743 patients were included, and outcomes were compared with those of GRAALL-2005 trial. The GRAALL-2014 study demonstrated reduced early mortality and higher complete remission rates in patients aged ≥45 years. MRD-guided transplantation decisions reduced allo-HSCT indications by ∼50%. Although older patients experienced a higher cumulative incidence of relapse, no significant difference in disease-free survival (DFS) was observed compared with historical cohorts across age subgroups. The overall 4-year DFS was 57.1% (95% confidence interval [CI], 53.4-61.1). Notably, 4-year overall survival improved significantly, from 65.5% (95% CI, 61.7-69.8) to 71.7% (95% CI, 67.7-76.0) in younger patients (P = .031) and from 49.6% (95% CI, 43.5-56.5) to 59.5% (95% CI, 53.5-66.3) in older patients (P = .011). These findings highlight the value of individualized treatment strategies that balance efficacy and safety. Future studies should investigate the integration of immunotherapy to further reduce treatment intensity and improve outcomes. This trial was registered at www.clinicaltrials.gov as #NCT02617004 and #NCT02619630.

Year:

2026

The T‐cell Leukemia Homeobox 1 ( TLX1 ) oncogene is frequently deregulated in T‐cell acute lymphoblastic leukemia (T‐ALL) and T‐cell lymphoblastic lymphoma (T‐LBL). In most instances, TLX1 overexpression results from its juxtaposition with a T‐cell receptor ( TCR ) locus caused by interchromosomal translocations. However, in the subset of non‐ TCR ‐translocated TLX1 ‐positive (non‐ TCR TLX1 +) T‐ALL cases, the underlying mechanisms driving TLX1 overexpression and their clinico‐biological implications remain unclear. By integrating high‐resolution data from next‐generation sequencing, fluorescence in situ hybridization, karyotyping, optical genome mapping, and long‐read whole‐genome sequencing across a cohort of 1122 adult and pediatric T‐ALL/T‐LBL cases, we identified TLX1 overexpression in 11% of T‐ALL/T‐LBL cases, with an unexpected 14% incidence of non‐ TCR TLX1 + cases among TLX1 + cases. Non‐ TCR TLX1 + T‐ALL cases show distinct clinico‐biological features, including a lower frequency of cortical phenotype compared to the TCR ‐translocated TLX1 + ( TCR TLX1 +) subgroup, regardless of TLX1 expression levels. In non‐ TCR TLX1 ⁺ cases, TLX1 deregulation results mostly (83%) from the hijacking of the ANKRD1 and PCGF5 enhancer at 10q23.31 through various chromosomal aberrations. Genomic analyses revealed that these aberrations juxtapose the ANKRD1 and PCGF5 enhancer with TLX1 , driving its overexpression. Importantly, survival analysis revealed that non‐ TCR TLX1 + patients had significantly poorer outcomes compared to their TCR TLX1 ⁺ counterparts (3y‐OS: 55% vs. 90%, P < 0.001 and 3y‐DFS: 45% vs. 75%, P = 0.02). These findings, consistent with our previous observations in TAL1 ‐driven T‐ALL, confirm that the clinico‐biological impact of an oncogene is influenced by the specific mechanism underlying its deregulation.

Year:

2025

Supplementary figure 1. Sequencing-based analysis of CNA and LOH in adult LH-ALL. Supplementary figure 2. Representation of mutations in the frequent targeted genes in adult LH-ALL. Supplementary figure 3. Longitudinal assessment of TP53-mutant cell fraction as determined by ddPCR along with clonal IG/TR-based MRD quantification in three patients with undetectable TP53 mutation at remission. Supplementary figure 4. Merged single-cell analysis of cell-surface markers by ADT-sequencing of remission samples from three LH-ALL patients. Supplementary figure 5. Individual single-cell analyses of cell-surface markers by ADT-sequencing of remission samples from three LH-ALL patients. Supplementary figure 6. Individual analyses of single-cell immunophenotyping and genotyping of remission samples from three LH-ALL patients. Supplementary figure 7. Evaluation of allelic dropout rate on heterozygous single nucleotide polymorphism (SNPs) in remission samples. Supplementary figure 8. Individual single-cell analysis of cell-surface markers by ADT-sequencing of diagnosis samples from three LH-ALL patients. Supplementary figure 9. Single-cell genotyping of heterozygous SNPs allowing LOH assessment in diagnosis samples from three LH-ALL patients. Supplementary Figure 10. Distribution of single-cell genotypes of two LH-ALL patients with persistent TP53 and JAK2 (EI_046) or DNMT3A (EI_035) mutations in remission samples.

Year:

2025

Supplementary Table 1. Karyotypes of LH-ALL patients at diagnosis. Supplementary Table 2. Somatic variants detected in LH-ALL patients at diagnosis. Supplementary Table 3. ARCH related variants detected in LH-ALL patients at remission. Supplementary Table 4. Minimal residual disease values of remission samples used for mutation analysis. Supplementary Table 5. Somatic alterations in cell populations from diagnostic samples (BMMC) based on single-cell analyses. Supplementary Table 6. Somatic alterations in FACS-sorted cell populations from diagnostic samples. Supplementary Table 7. Panel of genes for targeted sequencing. Supplementary Table 8. Single cell DNA amplicons for genotyping and LOH analyses. Supplementary Table 9. Single cell DNA amplicons for B-ALL clono-specific IG/TR detection. Supplementary Table 10. ADT-seq panel and spike-in antibodies. Supplementary Table 11. Single cell sequencing metrics.

Year:

2025

T‐cell acute lymphoblastic leukemia (T‐ALL) is a rare and aggressive hematological malignancy primarily affecting adolescents and young adults and is scarce in infants and toddlers under age 3. Unlike B‐ALL, T‐ALL in this young population remains poorly characterized due to limited data and lacks evidence‐based guidelines to help clinicians determine the optimal treatment approach. In this study, we conducted a comprehensive genetic analysis of infant/toddler T‐ALL cases from a French national cohort, utilizing high‐throughput targeted sequencing, optical genome mapping, and RNA sequencing. Genetic analysis revealed the absence of TLX1/3 dysregulation. Instead, we identified a significant prevalence of NKX2 rearrangements ( n = 9, 33%), co‐occurring with MYB alterations ( n = 5/9) or chromothripsis‐like events ( n = 3/9). Additional findings included TAL1/‐like anomalies (30%), STAG2::LMO2 (15%), ETS rearrangements (15%), and rarely, KMT2A rearrangements (7%). Comparative analyses with 245 patients aged 3–18 years, enrolled in the pediatric FRALLE2000T French protocol, underscored the distinct clinical and genetic profiles of infants/toddlers. Despite presenting with higher rates of hyperleukocytosis and slower responses to treatment, they demonstrated comparable survival outcomes to older pediatric patients, with a 5‐year overall survival (OS) rate of 75.4% (95% confidence interval [CI]: 60.0%–94.8%) versus 75.2% (95% CI: 69.8%–81.1%), p = 0.86. Notably, alterations in NKX2 , KMT2A , and STAG2::LMO2 delineated oncogenic subgroups exhibiting a remarkable 100% OS rate, while patients with TAL1 or ETS dysregulation experienced less favorable outcomes. This was further supported by analyses of data from the COG AALL0434 trial, enhancing our understanding of T‐ALL in infants/toddlers. Large‐scale collaborative studies remain essential to confirm these findings and refine treatment strategies.

Year:

2025

The deregulated activation of the phosphoinositide 3-kinase (PI3K) pathway is a hallmark of aggressive tumors with metabolic plasticity, eliciting their adaptation to the microenvironment and resistance to chemotherapy. A significant gap lies between the biological features of PI3K-driven tumors and the specific targeting of their vulnerabilities. Here, we explore the metabolic liabilities of PI3K-altered T-cell acute lymphoblastic leukemia (T-ALL), an aggressive hematological cancer with dismal outcomes. We report a metabolic crosstalk linking glutaminolysis and glycolysis driven by PI3K signaling alterations. Pharmaceutical inhibition of mTOR reveals the singular plasticity of PI3K-altered cells toward the mobilization of glutamine as a salvage pathway to ensure their survival. Subsequently, the combination of glutamine degradation and mTOR inhibition demonstrates robust cytotoxicity in PI3K-driven solid and hematological tumors in pre-clinical and clinical settings. We propose a novel therapeutic strategy to circumvent metabolic adaptation and efficiently target PI3K-driven cancer.

Year:

2025

Extranodal NK/T-cell lymphoma (ENKTCL) is an Epstein–Barr virus (EBV)–related neoplasm with male dominance and a poor prognosis. A better understanding of the genetic alterations and their functional roles in ENKTCL could help improve patient stratification and treatments. In this study, we performed a comprehensive genetic analysis of 178 ENKTCL cases to delineate the landscape of mutations, copy number alterations (CNA), and structural variations, identifying 34 driver genes including six previously unappreciated ones, namely, HLA-B , HLA-C , ROBO1 , CD58 , POT1 , and MAP2K1 . Among them, CD274 (24%) was the most frequently altered, followed by TP53 (20%), CDKN2A (19%), ARID1A (15%), HLA-A (15%), BCOR (14%), and MSN (14%). Chromosome X losses were the most common arm-level CNAs in females (∼40%), and alterations of four X-linked driver genes ( MSN , BCOR , DDX3X , and KDM6A ) were more frequent in males and females harboring chromosome X losses. Among X-linked drivers, MSN was the most recurrently altered, and its expression was lost in approximately one-third of cases using immunohistochemical analysis. Functional studies of human cell lines showed that MSN disruption promoted cell proliferation and NF-κB activation. Moreover, MSN inactivation increased sensitivity to NF-κB inhibition in vitro and in vivo . In addition, recurrent deletions were observed at the origin of replication in the EBV genome (6%). Finally, by integrating the 34 drivers and 19 significant arm-level CNAs, nonnegative matrix factorization and consensus clustering identified two molecular groups with different genetic features and prognoses irrespective of clinical prognostic factors. Together, these findings could help improve diagnostic and therapeutic strategies in ENKTCL. Significance: Integrative genetic analyses and functional studies in extranodal NK/T-cell lymphoma identify frequent disruptions of X-linked drivers, reveal prognostic molecular subgroups, and uncover recurrent MSN alterations that confer sensitivity to NF-κB inhibition.

Year:

2024

Extranodal NK/T-cell lymphoma (ENKTCL) is an Epstein–Barr virus (EBV)–related neoplasm with male dominance and a poor prognosis. A better understanding of the genetic alterations and their functional roles in ENKTCL could help improve patient stratification and treatments. In this study, we performed a comprehensive genetic analysis of 178 ENKTCL cases to delineate the landscape of mutations, copy number alterations (CNA), and structural variations, identifying 34 driver genes including six previously unappreciated ones, namely, HLA-B , HLA-C , ROBO1 , CD58 , POT1 , and MAP2K1 . Among them, CD274 (24%) was the most frequently altered, followed by TP53 (20%), CDKN2A (19%), ARID1A (15%), HLA-A (15%), BCOR (14%), and MSN (14%). Chromosome X losses were the most common arm-level CNAs in females (∼40%), and alterations of four X-linked driver genes ( MSN , BCOR , DDX3X , and KDM6A ) were more frequent in males and females harboring chromosome X losses. Among X-linked drivers, MSN was the most recurrently altered, and its expression was lost in approximately one-third of cases using immunohistochemical analysis. Functional studies of human cell lines showed that MSN disruption promoted cell proliferation and NF-κB activation. Moreover, MSN inactivation increased sensitivity to NF-κB inhibition in vitro and in vivo . In addition, recurrent deletions were observed at the origin of replication in the EBV genome (6%). Finally, by integrating the 34 drivers and 19 significant arm-level CNAs, nonnegative matrix factorization and consensus clustering identified two molecular groups with different genetic features and prognoses irrespective of clinical prognostic factors. Together, these findings could help improve diagnostic and therapeutic strategies in ENKTCL. Significance: Integrative genetic analyses and functional studies in extranodal NK/T-cell lymphoma identify frequent disruptions of X-linked drivers, reveal prognostic molecular subgroups, and uncover recurrent MSN alterations that confer sensitivity to NF-κB inhibition.

Year:

2024

Supplementary Figure 1 (A) Circos plot representing mutations co-occurrences in PHF6WT (left) and PHF6ALT T-ALL (right). (B) Variant allele frequencies (VAF) of mutations at diagnosis and relapse. Genes are ordered by decreasing VAF at diagnosis from left to right.

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Collaborators (39)

Florent Morio

Université de Nantes

FRANCE
View details

Sébastien Maury

Head, Prof

Assistance Publique - Hôpitaux de Paris

FRANCE
View details

Renaud Leclere

Institut Curie

FRANCE
View details

Junji Koya

Senior Staff Scientist

National Cancer Center Research Institute

JAPAN
View details

Emmanuel Clave

Université de Paris Faculté de Santé

FRANCE
View details

Olivier Lantz

Institut Curie

FRANCE
View details

Beat W. Schäfer

University Children's Hospital

SWITZERLAND
View details

Nicolas Boissel

Université Paris Cité

FRANCE
View details

Raphael Itzykson

MCU-PH

Université Paris Cité

FRANCE
View details

Salvatore Spicuglia

INSERM

FRANCE
View details

Felipe Suarez

Professor

Université Paris-Saclay

FRANCE
View details

Paul Saultier

Aix-Marseille University

FRANCE
View details

Akshay Joshi

University College London

UNITED KINGDOM
View details

Marie C. Béné

-

FRANCE
View details

Patrice Chevallier

-

FRANCE
View details

Seishi Ogawa

Kyoto University

JAPAN
View details

Koichi Ohshima

Professor

Kurume University

JAPAN
View details

Markus G. Manz

Department Chair

University Hospital of Zurich

SWITZERLAND
View details

Antoine Toubert

Head of laboratory

Université Paris Cité

FRANCE
View details

Keisuke Kataoka

Chief

National Cancer Center Research Institute

JAPAN
View details

Thomas Cluzeau

Centre Hospitalier Universitaire de Nice

FRANCE
View details

Jean‐Marie Michot

-

FRANCE
View details

Charlotte Smith

Institut Necker-Enfants Malades

FRANCE
View details

Sumito Shingaki

New York University

UNITED STATES
View details

Sylvain BAULANDE

Head

Institut Curie

FRANCE
View details

Hiroaki Miyoshi

Professor

Kurume University

JAPAN
View details

Stéphanie Gachet

Chercheuse contractuelle

INSERM

FRANCE
View details

Isabelle André

Université Paris Descartes

FRANCE
View details

Yasunori Kogure

Senior Researcher

National Cancer Center Research Institute

JAPAN
View details

Gandhi Damaj

Professor, M.D. Head of departement

University Hospital

FRANCE
View details

Paul Verweij

professor

Radboudumc

NETHERLANDS
View details

Simonin Mathieu

Institut Necker-Enfants Malades

FRANCE
View details

Coralie Guerin

Co-Head of EVs platform

Institut Curie

FRANCE
View details

lionel adès

Professor

-

FRANCE
View details

Laurence de Leval

Director of the Institute of Pathology / Professor of Pathology

Lausanne University Hospital

SWITZERLAND
View details

Sachiko Tsukita

-

JAPAN
View details

Koji Izutsu

Chief, Department of Hematology

National Cancer Center Hospital

JAPAN
View details

Yuki Saito

National Cancer Center Research Institute

JAPAN
View details

Sebastian Amigorena

-

FRANCE
View details